Literature DB >> 7831291

Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication.

G Natsoulis1, P Seshaiah, M J Federspiel, A Rein, S H Hughes, J D Boeke.   

Abstract

Capsid-targeted viral inactivation is an antiviral strategy in which toxic fusion proteins are targeted to virions, where they inhibit viral multiplication by destroying viral components. These fusion proteins consist of a virion structural protein moiety and an enzymatic moiety such as a nuclease. Such fusion proteins can severely inhibit transposition of yeast retrotransposon Ty1, an element whose transposition mechanistically resembles retroviral multiplication. We demonstrate that expression of a murine retrovirus capsid-staphylococcal nuclease fusion protein inhibits multiplication of the corresponding murine leukemia virus by 30- to 100-fold. Staphylococcal nuclease is apparently inactive intracellularly and hence nontoxic to the host cell, but it is active extracellularly because of its requirement for high concentrations of Ca2+ ions. Virions assembled in and shed from cells expressing the fusion protein contain very small amounts of intact viral RNA, as would be predicted for nuclease-mediated inhibition of viral multiplication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7831291      PMCID: PMC42740          DOI: 10.1073/pnas.92.2.364

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Reverse transcriptase encoded by a human transposable element.

Authors:  S L Mathias; A F Scott; H H Kazazian; J D Boeke; A Gabriel
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

2.  Assembly of type C oncornaviruses: a model.

Authors:  D P Bolognesi; R C Montelaro; H Frank; W Schäfer
Journal:  Science       Date:  1978-01-13       Impact factor: 47.728

3.  Helper-independent retrovirus vectors with Rous-associated virus type O long terminal repeats.

Authors:  J J Greenhouse; C J Petropoulos; L B Crittenden; S H Hughes
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

4.  Rapid cell culture assay technic for murine leukaemia viruses.

Authors:  R H Bassin; N Tuttle; P J Fischinger
Journal:  Nature       Date:  1971-02-19       Impact factor: 49.962

5.  Effect of chemical modification and fragmentation on antigenic determinants of internal protein p30 and surface glycoprotein gp70 of type C retroviruses.

Authors:  R J Versteegen; S Oroszlan
Journal:  J Virol       Date:  1980-03       Impact factor: 5.103

6.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.

Authors:  S Goff; P Traktman; D Baltimore
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

7.  Mutagenesis of the region between env and src of the SR-A strain of Rous sarcoma virus for the purpose of constructing helper-independent vectors.

Authors:  S Hughes; E Kosik
Journal:  Virology       Date:  1984-07-15       Impact factor: 3.616

8.  Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors.

Authors:  S H Hughes; J J Greenhouse; C J Petropoulos; P Sutrave
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

9.  Reverse transcriptase encoded by a retrotransposon from the trypanosomatid Crithidia fasciculata.

Authors:  A Gabriel; J D Boeke
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

10.  Phenotypes of murine leukemia virus-induced tumors: influence of 3' viral coding sequences.

Authors:  D E Ott; J Keller; K Sill; A Rein
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more
  10 in total

1.  Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo.

Authors:  G Schumann; M Hermankova; K Cannon; J L Mankowski; J D Boeke
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: application to a library of 50,000 compounds.

Authors:  Malgorzata Sudol; Jennifer L Fritz; Melissa Tran; Gavin P Robertson; Julie B Ealy; Michael Katzman
Journal:  Antivir Chem Chemother       Date:  2011-10-07

3.  Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyprotein significantly inhibits virus spread.

Authors:  M VanBrocklin; A L Ferris; S H Hughes; M J Federspiel
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures.

Authors:  G Schumann; L Qin; A Rein; G Natsoulis; J D Boeke
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Targeted ribonuclease can inhibit replication of hepatitis B virus.

Authors:  Jun Liu; Ying-Hui Li; Cai-Fang Xue; Jin Ding; Wei-Dong Gong; Ya Zhao; Yu-Xiao Huang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  A nonradioactive plate-based assay for stimulators of nonspecific DNA nicking by HIV-1 integrase and other nucleases.

Authors:  Malgorzata Sudol; Melissa Tran; Matthew G Nowak; John M Flanagan; Gavin P Robertson; Michael Katzman
Journal:  Anal Biochem       Date:  2009-09-11       Impact factor: 3.365

7.  Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.

Authors:  X Wu; H Liu; H Xiao; J Kim; P Seshaiah; G Natsoulis; J D Boeke; B H Hahn; J C Kappes
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

Review 8.  Targeting the Virus Capsid as a Tool to Fight RNA Viruses.

Authors:  Lucie Hozáková; Barbora Vokatá; Tomáš Ruml; Pavel Ulbrich
Journal:  Viruses       Date:  2022-01-18       Impact factor: 5.048

Review 9.  Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections.

Authors:  Xingcui Zhang; Renyong Jia; Jiakun Zhou; Mingshu Wang; Zhongqiong Yin; Anchun Cheng
Journal:  Viruses       Date:  2016-09-21       Impact factor: 5.048

Review 10.  A Defective Viral Particle Approach to COVID-19.

Authors:  Maria Kalamvoki; Vic Norris
Journal:  Cells       Date:  2022-01-17       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.